Holen Sie sich die Stockscreener-App
28.92
3.47%
-1.04
Schlusskurs vom Vortag:
$29.96
Offen:
$29.79
24-Stunden-Volumen:
811.73K
Relative Volume:
0.63
Marktkapitalisierung:
$3.64B
Einnahmen:
$236.00M
Nettoeinkommen (Verlust:
$-369.00M
KGV:
-9.0863
EPS:
-3.1828
Netto-Cashflow:
$-489.00M
1W Leistung:
-4.65%
1M Leistung:
+30.74%
6M Leistung:
+37.65%
1J Leistung:
+203.14%
1-Tages-Spanne:
$28.13
$29.79
1-Wochen-Bereich:
$28.13
$31.23
52-Wochen-Spanne:
$8.84
$31.73
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
28.92 | 3.64B | 236.00M | -369.00M | -489.00M | -3.1828 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | Hochstufung | Goldman | Neutral → Buy |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Form 144 Arcus Biosciences For: 9 July By Investing.com - Investing.com Nigeria
Trust files proposed RCUS Class A sales (RCUS) — multiple dates and amounts - Stock Titan
Arcus Biosciences awards stock options to five new employees - Stock Titan
(RCUS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer - AOL.com
Arcus Biosciences Announces New Employment Inducement Grants - AOL.com
Arcus Biosciences (RCUS) Surges 4.88% as Shares Test Key Resistance LevelThematic ETF Flow - dars.gov.et
Arcus Biosciences (RCUS) Gains Fresh Attention As Nature Study Puts Valuation Back In Focus - Sahm
How Investors Are Reacting To Arcus Biosciences (RCUS) Nature‑Published ARC‑20 Kidney Cancer Biomarker Data - Sahm
Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination - Yahoo Finance
RCUSArcus Biosciences Inc Latest SEC Filings - Finviz
Arcus kidney cancer drug shows 12.2-month median survival By Investing.com - Investing.com Nigeria
HIF-2a inhibition with casdatifan (IMAGE) - EurekAlert!
Arcus Biosciences (RCUS) Unveils Promising ARC-20 Study Findings on Casdatifan - GuruFocus
Arcus kidney cancer drug shows 12.2-month median survival - Investing.com
New research published in Nature links clinical activity with HIF‑2a biology in advanced kidney cancer patients treated with casdatifan - EurekAlert!
ETFs Investing in Arcus Biosciences, Inc. Stocks - TradingView
What Moves Stocks Higher? Last Week's 8 Healthcare Gainers - Forbes
(RCUS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arcus Biosciences Inc (RCUS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arcus Biosciences, Inc. (RCUS) reports Q1 loss, beats revenue estimates - MSN
RCUS Forecast — Price Target — Prediction for 2027 - TradingView
Arcus Biosciences, Inc. Actuals & Estimates (NYSE:RCUS) - TradingView
Arcus Biosciences president sells $877,501 in company stock By Investing.com - Investing.com India
Form 144 Arcus Biosciences For: 24 June By Investing.com - Investing.com Nigeria
Form 4 Arcus Biosciences Inc For: 24 June By Investing.com - Investing.com South Africa
Trust sells 25,000+ RCUS Class A shares (RCUS) in two Rule 144 transactions - Stock Titan
Arcus Biosciences president sells $877,501 in company stock - Investing.com
Arcus Biosciences Insider Sold Shares Worth $877,501, According to a Recent SEC Filing - Moomoo
Arcus Biosciences (RCUS) president sells 31K shares under 10b5-1 plan - Stock Titan
Arcus Biosciences, Inc. (RCUS) may report negative earnings: Know the trend ahead of next week's release - MSN
Arcus awards two new employees stock options, RSUs - Stock Titan
Arcus Biosciences stock hits 52-week high at $28.79 - Investing.com UK
Arcus Biosciences stock hits 52-week high at $28.79 By Investing.com - Investing.com Australia
Form 144 Arcus Biosciences For: 22 June By Investing.com - Investing.com Nigeria
RCUS (NYSE) plans sale of 25,000 Class A shares on 06/22/2026 - Stock Titan
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):